Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis

Journal of Rheumatology

Volumn 39, Issue 11, 2012, Pages 2066-2070

  Jayasundara, Kavisha S ^a   Keystone, Edward C ^b   Parker, Jayson L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biologics; Clinical trial risk; Disease modifying antirheumatic drug; Rheumatoid arthritis; Success rate

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84868371299     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120005     Document Type: Review

References (16)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
2. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6.
3. Bykerk VP, Baron M, Boire G, Haraoui B, Khraishi M, LeClercq S, et al. Canadian consensus statement on early optimal therapy in early rheumatoid arthritis. CRAJ 2004;14:11-3.
4. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
5. Lunt M, Watson K, Dixon W. No evidence of association between anti-tumour necrosis factor treatment and mortality in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:3145-53.
6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
7. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173-7.
8. Lee D, Weinblatt M. Review: Rheumatoid arthritis. Lancet 2001;358:903-11.
9. Polmar SH. New drugs for rheumatoid arthritis: The industry point of view [editorial]. Rheumatol Clin 2009;10:1-2.
10. US Food and Drug Administration. What is a biological product? [Internet. Accessed July 26, 2012.] Available from: http://www.fda.gov/AboutFDA/ Transparency/Basics/ucm194516.htm
11. DiMasi JA, Feldman L, Wilson A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 2010;3:272-7.
12. Parker JL, Zhang ZY, Buckstein R. Clinical trial risk in non-Hodgkin's lymphoma: Endpoint and target selection. J Pharm Pharmaceut Sci 2011;13:227-35.
13. Parker JL, Kohler JC. The success rate of new drug development in clinical trials: Crohn's disease. J Pharm Pharmaceut Sci 2010;13:191-7.
14. Osborne BJ, Kaul R, Parker JL. Drug development risk in HIV-1 clinical trials: The effect of drug class. J Pharmaceut Health Serv Res 2011;2:211-6.
15. Fogler WE. Treating rheumatoid arthritis with DMARDs and biologics. Drug Discovery World 2008. [Internet. Accessed July 26, 2012.] Available from: http://www.ddw-online.com/s/therapeutics/p92869/treating-rheumatoid-arthritis- with-dmardsand-biologicsfall-2008.html
16. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18.